Longitudinal Microbiome Changes in Children Exposed to Proton Pump Inhibitors.

Autor:	Zhang YJ; Gastroenterology/Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA.; Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Connearney S; Gastroenterology/Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA., Hester L; Gastroenterology/Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA., Du M; Gastroenterology/Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA., Catacora A; Gastroenterology/Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA., Akkara A; Gastroenterology/Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA., Wen A; Gastroenterology/Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA., Bry L; Massachusetts Host-Microbiome Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Clinical Microbiology Laboratory, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Alm EJ; Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Rosen R; Gastroenterology/Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA.
Jazyk:	angličtina
Zdroj:	Clinical and translational gastroenterology [Clin Transl Gastroenterol] 2024 Sep 01; Vol. 15 (9), pp. e1. Date of Electronic Publication: 2024 Sep 01.
DOI:	10.14309/ctg.0000000000000703
Abstrakt:	Introduction: Proton pump inhibitor (PPI) use has been associated with an increased risk of gastrointestinal and upper respiratory infections in children. There are limited longitudinal data on the effect of PPI in children. The goal of this prospective observational study was to compare the stool and oropharyngeal microbiome of children before and after starting PPIs. Methods: We prospectively recruited participants from a gastroenterology clinic. Consented participants provided stool samples and oropharyngeal swabs at baseline and after 8 weeks of PPI therapy. Microbiome changes were measured by analyzing 16S sequencing from both body sites at both time points. Results: Thirty-four participants completed the study and provided samples both at baseline and after 8 weeks on PPI therapy. Of those, 24 participants had sufficient sequencing from both stool and oropharyngeal samples at both time points. There were no differences between the pre-PPI and post-PPI samples using beta-diversity metrics in either the oropharynx or stool. There were, however, significant changes in specific taxa. There was an enrichment of Streptococcus in the stool after PPI use and a reduction in the relative abundance of Bifidobacterium , Peptostreptococcus , and Turicibacter ( P -values < 0.01). Furthermore, there was an increase in the relative abundance of oropharyngeal bacteria in the stool after PPI therapy. This enrichment of oropharyngeal bacteria in the stool was most prominent in younger participants. Discussion: Further investigation is needed to determine the clinical and microbial factors that predispose or protect against microbiome changes due to PPI use and why young children are more susceptible to this PPI effect. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu